ASX Penny Stocks To Watch: 3 Picks Under A$200M Market Cap

The ASX is poised for a strong start today, buoyed by positive corporate reporting and lower oil prices, even as global markets face mixed signals. For investors interested in exploring beyond the major players, penny stocks—often representing smaller or newer companies—continue to offer intriguing opportunities. Despite their somewhat outdated name, these stocks can present valuable growth potential when backed by solid financial fundamentals.

We'll examine a selection from our screener results.

AML3D (ASX:AL3)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: AML3D Limited provides 3D printing systems and contract manufacturing services to various industries including aerospace, marine, defence, oil and gas, mining, and general manufacturing across Australia, Singapore, and the United States with a market cap of A$75.13 million.

Operations: The company's revenue of A$6.01 million is generated from its 3D printing services and machinery sales.

Market Cap: A$75.13M

AML3D Limited, with a market cap of A$75.13 million, is currently trading significantly below its estimated fair value and has forecasted earnings growth of 71.8% per year. Despite being unprofitable and having increased losses over the past five years, the company maintains a strong cash position with short-term assets exceeding both short- and long-term liabilities. The management team and board are experienced, with average tenures of 3.2 and 5.4 years respectively. While AML3D's share price is highly volatile, it remains debt-free with no significant shareholder dilution in the past year.

• Unlock comprehensive insights into our analysis of AML3D stock in this financial health report.
• Evaluate AML3D's prospects by accessing our earnings growth report.

Alcidion Group (ASX:ALC)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Alcidion Group Limited develops and sells digital health software solutions for healthcare organizations in Australia, New Zealand, and the United Kingdom, with a market capitalization of A$128.98 million.

Operations: The company generates revenue primarily from its healthcare software solutions, amounting to A$51.64 million.

Market Cap: A$128.98M

Alcidion Group Limited, with a market capitalization of A$128.98 million, has shown consistent profitability over the past five years and reported revenue of A$51.64 million for fiscal year 2026. The company is actively seeking acquisitions to enhance its growth trajectory and expand into new markets, while also investing in AI and other healthcare solutions. Alcidion's earnings have grown significantly faster than the industry average, supported by a stable financial position with no debt and short-term assets covering both short- and long-term liabilities. However, its return on equity remains low at 2.5%.

• Take a closer look at Alcidion Group's potential here in our financial health report.
• Explore Alcidion Group's analyst forecasts in our growth report.

Nyrada (ASX:NYR)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Nyrada Inc. is a clinical-stage biotechnology company that develops small-molecule therapies for neuroprotection and cardioprotection in Australasia, with a market cap of A$192.73 million.

Operations: The company generates revenue of A$2.01 million from its focus on small molecule drug development.

Market Cap: A$192.73M

Nyrada Inc., a clinical-stage biotech firm, has a market cap of A$192.73 million but remains pre-revenue with minimal earnings of A$2.19 million for the fiscal year 2026, marking a decline from the previous year. Despite this, it maintains strong liquidity with short-term assets of A$10.4 million surpassing both its short- and long-term liabilities significantly. The company is debt-free and has sufficient cash runway to sustain operations for over a year even as losses have increased by 7% annually over five years. Its share price is highly volatile, reflecting broader market uncertainties typical in penny stocks.

• Jump into the full analysis health report here for a deeper understanding of Nyrada.
• Explore historical data to track Nyrada's performance over time in our past results report.

Summing It All Up

• Click here to access our complete index of 400 ASX Penny Stocks.
• Ready To Venture Into Other Investment Styles? These 21 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com